Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to assess, in a phase 1/2 study, the safety and efficacy of
this synthetic vaccine SLP-HPV-01® in HIV+ men with CD4 counts > 350 x 10E6/l and
HPV16-induced intra-anal high-grade AIN (grade 2-3) that failed on, or recurred after
previous treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators:
ISA Pharmaceuticals B.V. Leiden University Medical Center